ArticleCell death & disease2026
The deubiquitinase activity of CYLD is required for B cell differentiation.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
CYLD is a functional deubiquitinase, involved in the regulation of significant cellular functions, including survival and apoptosis. To elucidate the role of CYLD in B cell differentiation, we generated transgenic animals with targeted deletion of the catalytically active form of the protein in B cells, starting from early differentiation stages. Our results indicate that catalytic inactivation of CYLD leads to a severe reduction of mature B cells, associated with blockade of differentiation at the Pro B cell stage, altered distribution of B cell populations in the spleen and bone marrow, culminating in impaired immune responses to model antigens. Single cell RNA sequencing of bone marrow B cells confirmed the severe perturbation of lymphopoiesis. Mechanistically, we found impaired expression of the IL-7 receptor alpha chain (IL-7Ra) and its upstream transcriptional activator FOXO1, leading to defective IL-7 signaling that is vital for early B cell development. However, the substrate(s) deubiquitinated by CYLD that regulates the FOXO1-IL-7R pathway remains unclear. Overall, our data imply a crucial role for the deubiquitinase activity of CYLD in B cell lymphopoiesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.